EMIT is an innovative injectable hydrogel designed as a non-hormonal, reversible male contraceptive that empowers men to take control of their reproductive health. The product offers a unique solution for men seeking a reliable and non-invasive family planning method. By addressing a market need for effective, reversible contraceptive options, EMIT aims to fill a critical gap in the reproductive health space.
The current options for male contraception are limited, with existing methods such as condoms, spermicide, and the withdrawal method suffering from high failure rates. While vasectomies provide a permanent and highly effective solution, many men hesitate due to the invasive nature and permanence of the procedure. As a result, there is a significant unmet demand for a reversible, non-invasive, and effective male contraceptive method.
EMIT's injectable hydrogel offers a natural, non-hormonal, and reversible male contraceptive. It is designed to be a safe, reliable, and temporary method for men who want control over their reproductive health without permanent intervention. Whether in stable relationships, seeking to delay or prevent pregnancy, or exploring alternatives to vasectomies, EMIT provides a much-needed solution for men of reproductive age.
EMIT operates on a B2B2C model, working with key stakeholders in the healthcare ecosystem, including:
- Insurance companies for reimbursement strategies and broader coverage.
- Healthcare providers (especially urologists and family planning services) for distribution and patient engagement.
- Pharmacies and NGOs to expand access in communities and offer affordable solutions.
- Government agencies and family planning services to integrate EMIT into public health programs and initiatives.
This strategic approach allows us to leverage existing infrastructure, ensuring that EMIT reaches a broad audience efficiently.
The market for male contraception remains vastly underdeveloped, with existing methods lacking reliability and acceptability. Our target customers are men aged 18 and older who are actively seeking contraceptive options, particularly those looking for alternatives to vasectomy. This includes:
- Men in stable relationships who wish to prevent or delay pregnancy.
- Fathers looking for a temporary, non-invasive alternative to vasectomy.
- Men who are interested in having a reversible contraceptive option.
This underserved market presents a significant growth opportunity, as reproductive health for men is increasingly becoming a focus of attention in family planning.
EMIT has received national recognition and accolades for its innovation and progress (links to articles are embed on our website under product tab):
- 2022 NIH DEBUT Venture Prize Winner
- VentureWell E-Teams Phase I & II Awardee
- Mayo Clinic and ASU 1st Scorpion Tank Winner
- NSF I-Corps Hub Desert & Pacific Region Participant
- ASU Lab to Launch eSeed Challenge Winner
- ASU Venture Devils MedTech Venture Winner
We are seeking funding to:
- Secure international intellectual property (IP): This is critical to protecting our product globally and ensuring a strong market position.
- Complete proof-of-concept study: The funds will help us finalize the necessary studies and validate the product, positioning it for larger investment rounds and critical milestones.
EMIT’s success is not just about providing a new product to the market; it’s about changing the conversation around male reproductive health. By empowering men with more choices in contraception, we aim to significantly reduce the number of unintended pregnancies and promote equality in family planning.
Crowdfunding Link: https://givebutter.com/QeHQxe
Ready to Ask For Funding for your company?
Post a Funding Request